AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Nexsen Limited (ASX:NXN), a rising leader in rapid point-of-care diagnostics, has inaugurated a dedicated research and development center in Hong Kong, marking a major step in its Asia-Pacific expansion strategy. This new facility will drive the development and clinical validation of Nexsen's diagnostic technologies and advance two innovative programs focused on traumatic brain injury and neonatal sepsis. Strategically located, the lab brings Nexsen closer to key Asian healthcare regulators, distribution partners, and target patient groups as it targets entry into the US$5.36 billion Asia-Pacific point-of-care testing market.
Key Points
- Nexsen Limited (ASX:NXN) has launched a state-of-the-art R&D facility in Hong Kong to support its Asia-Pacific growth ambitions.
- The center will enhance development and commercialisation of rapid diagnostic technologies, complementing Nexsen's Australian operations through an integrated innovation platform.
- Two new diagnostic initiatives are underway, focusing on traumatic brain injury (affecting approximately 69 million people globally each year) and neonatal sepsis (responsible for about 15% of newborn deaths worldwide).
- Nexsen secured a HK$6 million Ignite grant and formed partnerships with four premier Hong Kong universities: University of Hong Kong, Chinese University of Hong Kong, City University of Hong Kong, and Hong Kong Metropolitan University.
- The Hong Kong facility is staffed by a dedicated local team of full-time researchers and complements Nexsen's existing Joint Research Facility with Universiti Malaya in Malaysia.
Strategic Entry Point into Asia-Pacific Point-of-Care Diagnostics Market
Nexsen chose Hong Kong for its main Asian laboratory to leverage the city’s role as a gateway to key Asian healthcare markets and its world-renowned research capabilities. Hong Kong’s accredited healthcare system and pivotal location within Asia’s healthcare ecosystem provide Nexsen with direct access to patient populations, clinicians, regulators, and distribution channels critical for regional market penetration. This facility integrates Nexsen into the Asia-Pacific healthcare infrastructure, significantly bridging the gap between research and target markets.
The Hong Kong facility complements Nexsen’s ongoing regional expansion efforts. The company’s receipt of a HK$6 million Ignite grant offers direct funding and access to further non-dilutive grants within Hong Kong’s innovation ecosystem, enabling advancement of research programs with minimal shareholder dilution. This strategic positioning also supports Nexsen’s commercial objectives by facilitating closer ties with regulators and distribution networks across Asia. Additionally, Nexsen is exploring future manufacturing expansion opportunities in Hong Kong to meet rising Asian market demand.
New Diagnostic Programs Addressing Critical Global Health Issues
Nexsen’s diagnostics pipeline now includes two major programs targeting significant unmet healthcare needs. The traumatic brain injury (TBI) program addresses a global health issue impacting an estimated 69 million individuals annually. Rapid TBI diagnosis is vital for treatment decisions and improved outcomes, yet early detection remains challenging in emergency settings. Nexsen’s rapid diagnostics platform aims to close this gap by enabling faster identification and treatment of TBI patients.
The neonatal sepsis program targets one of the leading causes of infant mortality worldwide. With approximately 2.3 million newborn deaths annually, sepsis accounts for around 15% of these fatalities. Early and accurate diagnosis is a critical unmet need, and the World Health Organization has prioritized improved diagnostics for neonatal sepsis to reduce infant mortality and antibiotic overuse. Both programs leverage clinical expertise and research capabilities from Nexsen’s Hong Kong university collaborations, expanding its scalable rapid diagnostics platform into globally significant healthcare markets.
Supporting and Expanding Existing Diagnostics Portfolio
Beyond the new initiatives, the Hong Kong lab will accelerate development across Nexsen’s existing diagnostics portfolio, which includes tests for Group B Streptococcus, acute kidney injury, chronic kidney disease, bovine mastitis, and biosecurity and food safety. This diverse pipeline showcases the flexibility of Nexsen’s proprietary biosensing platform across clinical and non-clinical applications. The facility will expedite development and clinical validation of current programs alongside the new TBI and neonatal sepsis projects.
The center will also facilitate ongoing evaluation of emerging diagnostic opportunities, enabling Nexsen to identify and pursue new applications in high-burden disease areas. Integrating the Hong Kong lab into Nexsen’s global R&D network enhances responsiveness to market demands and regulatory requirements throughout the Asia-Pacific region while maintaining rigorous scientific standards.
Integrated Australia-Hong Kong Innovation Platform Enhancing Scientific Collaboration
Nexsen has established an integrated innovation platform linking its Australian scientific expertise with direct access to Hong Kong’s leading healthcare and life sciences ecosystem. This geographic diversification allows the company to harness talent and institutional partnerships across both regions efficiently. The Hong Kong facility complements Australian operations, fostering a collaborative environment that accelerates product development and clinical validation.
The dedicated local research team in Hong Kong strengthens Nexsen’s capacity to manage regional research, clinical collaborations, and product development. This presence enables close cooperation with university, clinical, and healthcare partners, ensuring real-time alignment on research priorities and validation studies. The investment underscores Nexsen’s long-term commitment to Asia-Pacific market growth and positions the company to capitalize on evolving regulatory and commercial opportunities.
Collaborations with Four Leading Hong Kong Universities
Nexsen has formalized partnerships with four top Hong Kong universities, enhancing its research and clinical validation capabilities. The University of Hong Kong (HKU) supports microbiology research and validation of Group B Streptococcus diagnostics, providing infectious disease expertise. The Chinese University of Hong Kong (CUHK) contributes to neonatal intensive care, microbiology, and neonatal sepsis spectroscopy research, advancing newborn sepsis diagnostics. City University of Hong Kong (CityU) aids in aptamer characterization and biosensor development, underpinning Nexsen’s diagnostic technology. Hong Kong Metropolitan University (HKMU) facilitates applied research and translational collaboration, bridging laboratory research with clinical application.
These partnerships grant Nexsen access to specialized expertise, clinical networks, and patient populations essential for its diagnostics pipeline. The Hong Kong R&D hub consolidates these capabilities locally, fostering collaboration and accelerating the commercialization of clinically validated diagnostics. This multi-institutional approach broadens Nexsen’s research base and reduces reliance on any single partner.
Regional Research Network Connecting Hong Kong and Malaysia
The Hong Kong facility complements Nexsen’s UM–Nexsen Joint Research Facility with Universiti Malaya in Malaysia, forming a comprehensive Asia-Pacific innovation network. Together, these hubs enhance Nexsen’s integrated R&D and commercialisation capabilities across Southeast Asia and the broader region. This dual-facility strategy leverages diverse research strengths and institutional networks, providing access to varied clinical populations and regulatory environments relevant to different Asian markets.
This expanded infrastructure establishes Nexsen as a key player in Asia-Pacific healthcare innovation, capable of advancing multiple development programs across jurisdictions and disease areas. The complementary nature of the Hong Kong and Malaysia centers allows optimization of research activities based on local expertise, patient demographics, and regulatory requirements. As demand grows, this network lays the groundwork for manufacturing expansion and market entry, supporting Nexsen’s goal to lead rapid point-of-care diagnostics in the region.
Managing Director Highlights Strategic Importance of Hong Kong Expansion
Managing Director Mark Muzzin emphasized the Hong Kong facility as a pivotal element in Nexsen’s Asia-Pacific growth. He noted that the dedicated local R&D base enables closer collaboration with university, clinical, and healthcare partners, combining expertise, patient access, and translational capabilities established through Nexsen Hong Kong. This commitment reflects confidence in the substantial Asia-Pacific market potential and the necessity of permanent regional research infrastructure to seize these opportunities.
Muzzin highlighted the company’s focus on advancing its diagnostics portfolio, developing new traumatic brain injury and neonatal sepsis programs, and bringing innovation closer to end-users, regulators, and healthcare markets. This approach underscores Nexsen’s strategy to differentiate itself in the Asia-Pacific point-of-care diagnostics market by merging Australian scientific rigor with regional research infrastructure and clinical partnerships. The emphasis on proximity to users and regulators aligns research with regional healthcare needs and regulatory frameworks.
Scalable Biosensing Platform and Future Diagnostic Prospects
Nexsen’s proprietary biosensing platform is designed for scalability across diverse clinical applications, enabling pursuit of multiple high-burden disease diagnostics. The company is actively exploring additional opportunities beyond its current pipeline, demonstrating confidence in the platform’s adaptability to emerging clinical challenges. Its broad portfolio, spanning infectious diseases, kidney conditions, neurological and neonatal disorders, illustrates the platform’s capacity to meet varied diagnostic demands across patient populations and healthcare settings.
The Hong Kong facility supports this scalability by providing dedicated resources for ongoing evaluation and development. Nexsen’s flexible research program allows pursuit of emerging opportunities as identified, positioning the company as a platform technology provider capable of delivering multiple diagnostic solutions. Success depends on rigorous clinical validation and securing regulatory approvals across relevant Asian markets.
Company Overview and Market Position in Point-of-Care Diagnostics
Nexsen Limited is an emerging leader in rapid point-of-care diagnostics, focusing on delivering diagnostic results at or near patient care locations. This approach contrasts with centralized laboratory testing, which involves sample transportation and processing delays. Point-of-care diagnostics facilitate faster clinical decisions and are especially valuable in emergency care, remote areas, and resource-limited settings. The Asia-Pacific point-of-care testing market, valued at US$5.36 billion, presents significant commercial opportunities for efficient, cost-effective diagnostic solutions tailored to regional healthcare needs.
By establishing regional research and manufacturing infrastructure, Nexsen aims to move beyond technology licensing and export models toward direct engagement in Asia-Pacific healthcare markets. Embedding R&D within Asian healthcare ecosystems enables Nexsen to better understand local regulatory landscapes, clinical practices, and infrastructure factors influencing point-of-care diagnostic adoption. This strategy aligns with global trends favoring decentralized diagnostics and rapid testing to enhance healthcare efficiency and patient outcomes across diverse settings.
